Empagliflozin in type 1 diabetes

References

• Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care . 2016;39(8):1378–1383. doi:10.2337/dc15-2399 27411699
   PubMed Web of Science ®Google Scholar
• Libman IM , Miller KM , DiMeglio LA , et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. Jama . 2015;314(21):2241–2250. doi:10.1001/jama.2015.16174 26624824
   PubMed Web of Science ®Google Scholar
• Qiao Y-C , Ling W , Pan Y-H , et al. Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Oncotarget . 2017;8(39):66504–66515. doi:10.18632/oncotarget.16008 29029531
   PubMedGoogle Scholar
• Al Khalifah RA , Alnhdi A , Alghar H , Alanazi M , Florez ID . The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr Diabetes . 2017;18(7):664–673. doi:10.1111/pedi.12493 28145083
   PubMed Web of Science ®Google Scholar
• Ahren B , Hirsch IB , Pieber TR , et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care . 2016;39(10):1693–1701. doi:10.2337/dc16-0690 27493132
   PubMed Web of Science ®Google Scholar
• Mathieu C , Zinman B , Hemmingsson JU , et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care . 2016;39(10):1702–1710. doi:10.2337/dc16-0691 27506222
   PubMed Web of Science ®Google Scholar
• Davies MJ , D’Alessio DA , Fradkin J , et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care . 2018;41(12):2669–2701. doi:10.2337/dci18-0033 30291106
   PubMed Web of Science ®Google Scholar
• Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720 26378978
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377(7):644–657. doi:10.1056/NEJMoa1611925 28605608
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2019;380(4):347–357. doi:10.1056/NEJMoa1812389 30415602
   PubMed Web of Science ®Google Scholar
• Dandona P , Mathieu C , Phillip M , et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care . 2018;41(12):2552–2559. doi:10.2337/dc18-1087 30352894
   PubMed Web of Science ®Google Scholar
• Scheen AJ . Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet . 2014;53(3):213–225. doi:10.1007/s40262-013-0126-x 24430725
   PubMed Web of Science ®Google Scholar
• Perkins BA , Cherney DZI , Soleymanlou N , et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One . 2015;10(11):e0141085. doi:10.1371/journal.pone.0141085 26544192
   PubMed Web of Science ®Google Scholar
• Pieber TR , Famulla S , Eilbracht J , et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab . 2015;17(10):928–935. doi:10.1111/dom.12494 26080652
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Marquard J , Laffel LM , et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care . 2018;41(12):2560–2569. doi:10.2337/dc18-1749 30287422
   PubMed Web of Science ®Google Scholar
• Peters AL , Henry RR , Thakkar P , Tong C , Alba M . Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care . 2016;39(4):532–538. doi:10.2337/dc15-1995 26989182
   PubMed Web of Science ®Google Scholar
• Garg SK , Henry RR , Banks P , et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med . 2017;377(24):2337–2348. doi:10.1056/NEJMoa1708337 28899222
   PubMed Web of Science ®Google Scholar
• Buse JB , Garg SK , Rosenstock J , et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care . 2018;41(9):1970–1980. doi:10.2337/dc18-0343 29937430
   PubMed Web of Science ®Google Scholar
• Danne T , Cariou B , Banks P , et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care . 2018;41(9):1981–1990. doi:10.2337/dc18-0342 29937431
   PubMed Web of Science ®Google Scholar
• Mathieu C , Dandona P , Gillard P , et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care . 2018;41(9):1938–1946. doi:10.2337/dc18-0623 30026335
   PubMed Web of Science ®Google Scholar
• Dandona P , Mathieu C , Phillip M , et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol . 2017;5(11):864–876. doi:10.1016/S2213-8587(17)30308-X 28919061
   PubMed Web of Science ®Google Scholar
• Danne T , Garg S , Peters AL , et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with Sodium-Glucose Cotransporter (SGLT) inhibitors. Diabetes Care . 2019. doi:10.2337/dc18-2316
   Web of Science ®Google Scholar
• Ferrannini G , Hach T , Crowe S , Sanghvi A , Hall KD , Ferrannini E . Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care . 2015;38(9):1730–1735. doi:10.2337/dc15-0355 26180105
   PubMed Web of Science ®Google Scholar
• Cherney D , Lund SS , Perkins BA , et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia . 2016;59(9):1860–1870. doi:10.1007/s00125-016-4008-2 27316632
   PubMed Web of Science ®Google Scholar
• Herrington WG , Preiss D , Haynes R , et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J . 2018;11(6):749–761. doi:10.1093/ckj/sfy090 30524708
   PubMed Web of Science ®Google Scholar